Background: Erectile dysfunction (ED) is a common male sexual disorder. The relative benefits and harms of pharmacologic therapies for ED, as well as the value of hormonal testing in men with ED, are uncertain.
endocrinologic screening in the initial evaluation of all men with ED (15) (16) (17) (18) (19) (20) . In contrast, the American Urological Association recommends that hormone testing in men with ED be based on initial clinical assessment (for example, decreased libido, small testes, and reduced body hair) or failure of initial PDE-5 therapy management (5) . Whether this targeted approach for identifying and treating hormonal disorders as underlying causes of ED is appropriate has not been rigorously evaluated (13, 15, 20, 21) .
The aims of our review were to systematically identify and synthesize the published evidence to determine 1) the relative benefits and harms of oral PDE-5 inhibitors and hormonal treatments of ED, including the effect of patient characteristics and comorbid conditions on the likelihood of treatment success and 2) the clinical value of hormonal blood testing for identifying treatable causes of ED (for example, hypogonadism) and improving its outcomes.
We summarized and updated evidence from a technical review prepared for the Agency for Healthcare Research and Quality (22) and adapted the article in collaboration with the American College of Physicians' Clinical Efficacy Assessment Subcommittee to inform the development of its clinical practice guideline on this topic. The article focuses more specifically than the Agency for Healthcare Research and Quality technical review on treatments likely to be prescribed by primary care physicians. The topic of diagnosis and treatment of ED, as a subject for systematic review, was originally nominated by the American College of Physicians.
METHODS

Data Sources and Searches
We searched for English-language articles in MEDLINE (1966 
Study Selection
To assess the relative benefits and harms of pharmacologic treatments for ED, we selected randomized, controlled trials (RCTs) of pharmacologic treatments in men aged 18 years or older with ED. Treatments not generally prescribed by primary care physicians, such as vacuum constriction devices, intraurethral suppositories, intracavernosal injections, or psychotherapy, were considered beyond the scope of this review and are addressed in the technical report.
To assess the risks for nonarteritic anterior ischemic optic neuropathy (NAION) in PDE-5 inhibitor users, we selected RCTs; nonrandomized, controlled trials; and observational studies. To assess the clinical value of routine hormonal blood tests in men with ED, we selected studies that reported prevalence of hypogonadism, hyperprolactinemia, or both in men with ED and all RCTs comparing hormone treatment alone or in combination versus control in men with ED.
We excluded reviews, pooled analyses, editorials, commentaries, and letters. Two independent reviewers screened all identified titles and abstracts and, for articles considered potentially eligible, abstracted their full-text reports. Discrepancies were discussed and resolved by consensus. Appendix Figure 1 (available at www.annals.org) shows the literature selection process.
Data Extraction and Quality Assessment
Two reviewers independently abstracted data on study, population, and treatment characteristics. Treatment efficacy outcomes were the proportion of successful sexual intercourse attempts based on either participants' diaries or event logs (erection sufficiently hard and long-lasting for satisfactory intercourse) or participants' responses to question 3 of the Sexual Encounter Profile (SEP) (erection lasted long enough for successful intercourse) (23) ; the improvement in erectile function based on either participants' self-reports of improved erections (global assessment or efficacy question 1) or the mean Erectile Function domain score of the International Index of Erectile Function (IIEF) (24) ; and participants' responses to IIEF questions 3 (successful penile penetration) and 4 (maintenance of erection after penetration) (24) .
Abstracted adverse events data were the number of patients with any adverse event, specific adverse events, withdrawals due to adverse events, serious adverse events, and serious cardiovascular adverse events. We assessed the prevalence of hypogonadism or hyperprolactinemia by using the definitions provided by study authors, even though these may have differed between studies.
We evaluated the overall strength of evidence by using a method developed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group (25) . We used the Jadad scale to assess the methodological and reporting quality of RCTs (score range, 0 to 5; higher score indicates better quality) (26) . We judged the adequacy of allocation concealment to be adequate, inadequate, or unclear by using the approach proposed by Schulz and Grimes (27) . We assessed the quality of studies reporting serum hormonal levels by using a subset of the Quality Assessment Tool of Diagnostic Accuracy Studies (questions 1, 2, 8, 12, and 14) (28) . To explore the overall risk for bias, we generated risk-for-bias graphs (29) . Appendix A (available at www.annals.org) includes all evidence and quality assessment tables and risk-for-bias graphs for the included studies.
Data Synthesis and Analysis
We qualitatively summarized data on study (design, reporting quality, and sample size), population (age, severity of ED, and comorbid conditions), and treatment characteristics (dose, frequency, and duration). We considered studies suitable for pooling if they used the same design (RCT), enrolled similar populations (trials restricted to participants with a specific comorbid condition vs. those enrolling participants with a heterogeneous profile of comorbid conditions), evaluated the same type of treatment (for example, sildenafil), and reported the same efficacy or safety outcomes. We used DerSimonian and Laird random-effects models to generate pooled estimates of relative risks (RRs) and weighted mean differences (WMDs) with 95% CIs (30) . To avoid double-counting during pooling of a trial with several PDE-5 dose groups versus placebo, we used a generic inverse variance method to combine data from these groups for a single estimate of mean response rate versus placebo. Statistical heterogeneity was evaluated using a chi-square test and the I 2 statistic (low ϭ 25.0%; moderate ϭ 50.0%; high ϭ 75.0%) and was explored through subgroup and sensitivity analyses (for example, study quality and random-or fixed-effects model) (31) . We defined the subgroups a priori with respect to severity (mild, severe, or moderate) and cause (psychogenic, mixed, or organic) of ED, treatment (for example, dose [50 mg When studies did not adequately report summary statistics (such as treatment group mean score and SD), we calculated the needed variables if data for individual patients were reported. If a study reported only an SE of the mean response, we converted it to an SD. Trials were not incorporated into meta-analyses if the needed data (means [SDs]) could not be derived, and crossover trials did not report precrossover data. We included trials with no events for harms in the meta-analyses.
We examined the extent of publication bias through visual inspection of funnel plot asymmetry (32) and linear regression-based tests proposed by Egger and colleagues (33) . We performed analyses with R software, version 2.4.0 (www.r-project.org), and STATA software, version 11 (StataCorp, College Station, Texas).
Role of the Funding Source
The Agency for Healthcare Research and Quality provided funding. The funding source suggested the initial research questions and provided copyright release for this manuscript but had no role in the design, conduct, analysis, or reporting of the data or in the decision to submit the manuscript for publication.
RESULTS
Literature Flow
Our literature search (Appendix Figure 1, In total, 130 RCTs (160 main and secondary publications) evaluating oral PDE-5 inhibitors met eligibility criteria. These included 72 RCTs of sildenafil (34 -102) , 27 RCTs of vardenafil (23, , 28 RCTs of tadalafil (129 -156) , 2 RCTs of mirodenafil (157, 158) , and 1 RCT of udenafil (159) . In addition, 4 RCTs directly compared PDE-5 inhibitors (160 -163).
Most trials (Ͼ70.0%) were parallel-group and placebo-controlled and had only short-term follow-up (Յ12 weeks). Most were conducted in North America or Europe and were funded by the pharmaceutical industry. Trials enrolled heterosexual adult men with ED of various causes. Exclusion criteria common to most trials were penile or testicular deformity, cardiovascular conditions, use of nitrates, prostate cancer, HIV/AIDS, major hepatic or renal disease, spinal cord injury, and major psychiatric disorder. Nearly half of vardenafil trials and one third of tadalafil trials excluded men with ED that did not respond to previous PDE-5 inhibitor therapy or those who had discontinued PDE-5 inhibitor therapy because of adverse events. The efficacy and harms for 2 novel PDE-5 inhibitors, mirodenafil (157, 158) Among 4 RCTs that directly compared PDE-5 inhibitors, all had a crossover design and reported patient treatment preference as their primary outcome measure (160 -163). It was not clear whether these trials used an appropriate randomization method, 2 trials were not described as double-blind (160, 163) , and 2 restricted sildenafil to less than the standard maximum dosing (161, 162). All 4 trials reported reasons for and proportions of withdrawals or dropouts. Three trials were sponsored by the manufacturer of tadalafil (Appendix A: Figure 2 (85, 88, 97, 98) .
In 13 trials of vardenafil that enrolled men with a wide spectrum of comorbid conditions, the percentages of successful sexual intercourse attempts based on SEP question 3 in vardenafil and placebo groups were 68.0% (range, 50.0% to 88.0%) and 35.0% (range, 20.0% to 49.0%), respectively (23, 104, 106, 109, 110, 115, 117-119, 121, 122, 125, 127) . The diary or event log-based, weighted mean per-patient percentage of successful sexual intercourse attempts for vardenafil-treated patients was 73.0% versus 38.0% for placebo recipients (107, 112) ( Table 1 ). In 2 trials from which data pooling was possible (Appendix B: Figure 2) , the WMD in improvement from baseline in the percentage of successful intercourse attempts was 33.2 (CI, 26.0 to 40.3) in favor of vardenafil (106, 117) .
In 15 trials of tadalafil that enrolled men with a wide spectrum of comorbid conditions, the percentages of successful sexual intercourse attempts based on SEP question 3 were 69% (range, 50.0% to 85.0%) for tadalafil versus 33% (range, 23.0% to 52.0%) for placebo (131, 132, 134 -136, 138, 139, 142, 144, 148 -152, 154) . The mean per-patient percentage of successful intercourse attempts was 48.0% for tadalafil-treated patients and 9.0% for placebo recipients, based on diary or event logs (1 trial) (Table 1) (153). In 5 trials from which data pooling was possible (Appendix B: Figure 3) , the WMD in improvement from baseline in the percentage of successful intercourse attempts was 35.1 (CI, 26.9 to 43.3) in favor of tadalafil (132, 135, 139, 142, 148 (58), and renal failure (84, 123) (Appendix Figures 2 to 4) . Improvement in sexual intercourse success and erectile function was greater with higher versus lower doses of sildenafil (50 mg vs. 25 mg, but not 100 mg vs. 50 mg) and vardenafil (20 mg vs. 10 mg vs. 5 mg) but not tadalafil (20 mg vs. 10 mg vs. 5 mg) or mirodenafil (50 mg vs. 100 mg vs. 150 mg) (42, 48, 51, 72, 103, 107, 108, 110, 112, 122, 156 -159) . In 1 trial, men preferred tadalafil on-demand therapy rather than scheduled dosing 3 times per week, although the mean per-patient proportion of successful intercourse attempts or mean IIEF Erectile Function domain score did not differ (129) . In another trial, on-demand and once-daily vardenafil, 10 mg, produced similar treatment effects on the mean Erectile Function domain score in men with mild to moderate ED (124) .
Among men assigned to PDE-5 inhibitors, those with severe baseline ED experienced significantly greater absolute improvements in the IIEF scores than did those with mild baseline ED. However, men with severe ED still had worse end-of-treatment Erectile Function domain scores than did men with mild baseline ED (37, 46, 66, 110, 112, 131, 149, 151, 152) . There was no obvious treatment effect modification by the duration or cause of ED (42, 44, 51, 70, 74, 112) .
PDE-5 Inhibitor Versus PDE-5
Inhibitor. In 4 trials (160 -163), improvements in outcomes between PDE-5 inhibitors were inconsistent. Between-group differences in the mean IIEF Erectile Function domain scores were either statistically nonsignificant or significant but of small magnitude. In 1 trial (160), the use of 10-to 20-mg tadalafil was associated with a small but statistically significantly greater improvement in the mean proportion of successful sexual intercourse attempts compared with 25-to 100-mg sildenafil (76.9% vs. 72.2%; P ϭ 0.003). In the same trial, mean change in Erectile Function domain scores did not differ between groups. In a second trial, mean Erectile Function domain scores were similar between men receiving 100-mg sildenafil and men receiving 20-mg tadalafil (163) ( Table 1) . More men preferred 20-mg tadalafil (range, 52.2% to 73.0%) to 50-mg sildenafil (range, 27.0% to 33.7%) or 20-mg vardenafil (20.0%).
Clinical Guidelines
Oral PDE-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction Evidence from 2 low-quality RCTs was insufficient to determine whether testosterone (gel, 1 trial; patch, 1 trial) ϩ PDE-5 inhibitor was more effective than placebo ϩ PDE-5 inhibitor in improving the frequency or percentage of successful sexual intercourse attempts.
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Extent of Publication Bias
Visual inspection suggested asymmetry in the sildenafil, vardenafil, and tadalafil funnel plots for the rates of improved erection (Appendix C, available at www.annals .org). The linear regression test confirmed statistically significant asymmetry for all 3 funnel plots: sildenafil (P Ͻ 0.001), vardenafil (P ϭ 0.003), and tadalafil (P Ͻ 0.001).
Harms
PDE-5 Inhibitor Versus Placebo.
A greater proportion of men treated with PDE-5 inhibitors than men who received placebo had at least 1 adverse event ( Table 2) . The most commonly reported adverse events were headache, flushing, rhinitis, and dyspepsia (Appendix D, available at www.annals.org). Other reported events were visual disturbances, myalgia, nausea, diarrhea, vomiting, dizziness, and chest pain. In general, these events were mild to moderate and were transient. Serious adverse events were reported in fewer than 2.0% of participants, and incidence did not differ between PDE-5 inhibitor recipients and placebo recipients. In 58 placebo-controlled trials reporting data, risk for a serious cardiovascular event (such as fatal or nonfatal myocardial infarction, stroke, or severe angina) seemed higher in men treated with sildenafil (0.5%) than in men receiving placebo (0.1%). The risk for serious cardiovascular events was similar in men treated with vardenafil (0.2%) or tadalafil (0.3%) compared with placebo (range, 0.1% to 0.2%). Because many PDE-5 inhibitor trials were unbalanced with respect to the number of men randomly assigned in each treatment group, the estimated Peto odds ratios may have been prone to bias (29) and therefore are not presented here.
PDE-5 Inhibitor Versus PDE-5 Inhibitor. Differences in the incidence of any adverse events among men treated with sildenafil (range, 24.0% to 34.0%), tadalafil (range, 28.0% to 35.0%), and vardenafil (27.0%) were not statistically significant (Table 2) (160 -163). Discontinuation due to adverse effects ranged from 0.5% to 3.8% during tadalafil treatment, 0.5% to 3.8% during sildenafil treatment, and 1.0% during vardenafil treatment. The frequency of specific adverse events (headache, flushing, dyspepsia, and nasal congestion) seemed similar among treatments. Tadalafil may have been associated with more frequent myalgia (range, 2.3% to 4.4%) than sildenafil or vardenafil (range, 0% to 0.5%).
NAION or Priapism. Evidence on the incidence of NAION associated with use of PDE-5 inhibitors was limited to 10 case reports (165-174), 2 case series (175, 176) , and 1 retrospective cohort study (177) . In the cohort study, NAION and "possible" optic neuropathy were identified by using medical diagnostic codes, with NAION defined as ischemic nonarteritic optic neuropathy in the absence of temporal arteritis and polymyalgia rheumatica and "possible" NAION defined as papillitis, optic neuritis, or both in the absence of temporal arteritis, polymyalgia rheumatica, and previous optic neuropathies. Among more than 4 million male veterans aged 50 years or older, those prescribed PDE-5 inhibitors (11.5% of the cohort) had a risk for NAION similar to that of those who were not prescribed PDE-5 inhibitors (absolute rates of 4.6 and 4.5 cases per 10 000 men per year, respectively; RR, 1.02 [95% CI, 0.92 to 1.12]), but they had an increased risk for "possible" NAION (RR, 1.34 [CI, 1.17 to 1.55]) (177). Trials did not report the incidence of priapism, although the incidence of prolonged erection and priapism has been reported infrequently in PDE-5 inhibitor users during postmarketing surveillance (178) .
Hormonal Treatments Study and Population Characteristics
Fifteen RCTs evaluated the efficacy of hormonal therapy (oral, intramuscular, gel, cream, or patch testosterone) in hypogonadal men with ED (179 -193) . The criteria for defining men as hypogonadal varied widely across the trials, and some trials enrolled men both with and without ED (187-189, 191) . Three trials were restricted to men with HIV (186), major depressive disorder (190) , or dia- Higher dose (50 mg vs. 100 mg vs. 150 mg) corresponded to an increased incidence of any AEs. In both trials, the most common events were flushing (n ϭ 32), headache (n ϭ 23), nausea (n ϭ 5), eye redness (n ϭ 8), and dizziness (n ϭ 2).
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Udenafil vs. Evidence from 4 RCTs (2 low-quality RCTs) was insufficient to draw conclusions on risk for AEs. Incidence of headache, flushing, or dyspepsia was generally similar between groups.
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Clinical Guidelines Oral PDE-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction betes (185) . Only 60.0% of the trials were described as double-blind. The appropriateness of randomization and blinding method was not clear for 87.0% and 93.0% of trials, respectively. Only 1 trial reported adequate allocation concealment (182) . Given the uncertainty in these quality domains (randomization, blinding, and allocation concealment) and the differences among study populations, the overall strength of evidence was graded as low ( Table 1 and Appendix A: Figure 3 ).
Efficacy
Hormonal Therapy Versus Placebo. Results of trials comparing oral, intramuscular, or patch testosterone with placebo in hypogonadal men with ED were inconsistent regarding their effects on erectile function, degree of erection, or improved erection, with most indicating that testosterone was no more effective than placebo ( Table 1) . In 1 trial, gel testosterone (50 to 100 mg) but not patch testosterone modestly improved sexual intercourse frequency compared with placebo (180). In another trial (193) , men treated with testosterone gel (50 mg/d) had slightly higher mean IIEF Erectile Function domain scores than did placebo recipients (21.6 vs. 18.1; P Ͻ 0.01).
Hormonal Therapy Plus PDE-5 Inhibitor Versus PDE-5 Inhibitor Alone. Three small trials in hypogonadal men with ED refractory to previous PDE-5 inhibitor therapy yielded inconsistent results on whether oral PDE-5 inhibitor plus testosterone improved sexual function more than did PDE-5 inhibitor alone ( Table 1 ). In the first trial, 100-mg sildenafil plus 5-mg/d patch testosterone improved several measures of sexual intercourse success and erectile function compared with sildenafil plus placebo (183) . In the second trial, men randomly assigned to 100-mg sildenafil plus 1.0% gel testosterone had no greater frequency of sexual intercourse success than men randomly assigned to sildenafil plus placebo; they had small improvements on Four RCTs (2 low-quality RCTs) suggested that men receiving tadalafil had a higher incidence of myalgia (range, 2.0%-4.0%) than did those sildenafil (range, 0%-0.5%) and vardenafil (0%). AE ϭ adverse event; CV ϭ cardiovascular; MI ϭ myocardial infarction; PDE-5 ϭ phosphodiesterase-5; RCT ϭ randomized, controlled trial; RR ϭ relative risk. * See also Appendix D, available at www.annals.org. † Criteria for assigning grade: study design, consistency in results, precision around an effect estimate, and directness. Based on the approach of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) working group (25) : high ϭ further research is unlikely to change our confidence in the estimate of effect; moderate ϭ further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low ϭ further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low ϭ any estimate of effect is very uncertain. ‡ Hormonal treatments include oral, intramuscular, gel, cream, or patch testosterone.
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Hormonal Therapy Versus Placebo. The incidence of any (or treatment-related) adverse events did not differ between oral or gel testosterone and placebo groups (179, 180, 193) . Men receiving patch testosterone had a higher rate of application-site skin reactions and increased hematocrit than men receiving gel testosterone or placebo (180, 194, 195) . In 1 trial (180), 2 men treated with patch testosterone developed prostate cancer ( Table 2) . Prostate-specific antigen levels were similar in testosterone and placebo groups in 3 trials reporting these data (182, 191, 192) .
Hormonal Therapy Plus PDE-5 Inhibitor Versus PDE-5 Inhibitor Alone. In 3 trials, the incidence of adverse events was low and did not differ between sildenafil alone versus sildenafil plus patch, gel, or oral testosterone groups ( Table  2 ) (181, 183, 187) . Prostate-specific antigen levels were not significantly higher in the sildenafil plus testosterone groups than in the sildenafil-alone groups in 2 trials reporting these data (183, 187) .
Clinical Utility of Routine Hormonal Blood Tests in Men With Erectile Dysfunction Study and Population Characteristics
Twenty-nine studies (30 publications) were included, of which 28 (13, 15, 196 -222) and 10 (13, 15, 197, 199, 200, 205, 207, 212, 213, 223) reported measurements of testosterone and prolactin, respectively. Patients were recruited predominately from specialty clinics (for example, urology, sexual dysfunction, and endocrinology). Participants' mean age across studies ranged from 47 to 60 years.
About 80.0% of the studies reported at least some information on the hormonal test method. Most of the studies did not report on withdrawals or dropouts. Only 60.0% of studies described participant selection criteria clearly (Appendix A: Figure 4) . Given between-study variability in populations, hormone measurement methods, and prevalence rates of hormonal abnormalities, we rated the overall quality of evidence for the association of hormonal abnormalities with ED as low.
Prevalence of Hypogonadism and Hyperprolactinemia in Men With ED
The prevalence of low total testosterone levels (197, 208, 219, 220) , low free testosterone levels (206, 214) , and hyperprolactinemia (199, 212, 213) in men with ED varied widely across studies, with limited data from U.S. primary care settings or U.S. population representative samples. In 1 primary care clinic study, 24.1% of men with ED had total testosterone levels less than 10 nmol/L (Ͻ288 ng/dL) (205) . In a study of veterans recruited from an outpatient registry, 14.0% with "inadequate" erectile function had free testosterone levels less than 9.0 pg/mL (206) .
By comparison, in a study based in 1 ED specialty clinic, 36.0% of 157 consecutively referred men with ED had hypogonadism (total testosterone level Ͻ300 ng/dL) (219) . In a retrospective chart review of 2794 men presenting to a Veterans Affairs ED specialty clinic between 1987 and 2002 with a symptom of ED, 654 (23.0%) had androgen deficiency (total testosterone level Ͻ300 ng/dL) (220) .
In Boston Area Community Health Survey's populationbased stratified random sample of men aged 30 to 79 years, the prevalence of total testosterone levels less than 300 ng/dL was 35.0% in men with ED and 22.7% in men without ED (216) . In another population-based cohort of men aged 40 to 70 years, the Massachusetts Male Aging Study, there was no association between ED and total testosterone, bioavailable testosterone, or sex hormonebinding globulin after adjustment for potentially confounding variables (217) .
Overall, these data suggest that variability in prevalence estimates may reflect between-study differences in population characteristics, hormonal measurement methods, or diagnostic criteria for ED or hormonal abnormalities. Studies were inconsistent regarding whether, among men with ED, those with and without hypogonadism differed in age, severity or duration of ED, or prevalence of chronic diseases (13, 15, 199, 201, 204, 207, 212, 218, 224) . Among men with ED in specialty clinic populations, those with low sexual desire, premature ejaculation, or testicular atrophy tended to have low testosterone levels (13, 15, 204, 207, 218) . In 1 of these studies, the men with low sexual desire also were more likely to have hyperprolactinemia (207). We could not identify studies examining the rate of hormonal abnormalities in men whose initial PDE-5 inhibitor treatment failed. Overall, evidence was insufficient to determine whether, in primary care clinics, men with ED (or specific subgroups of men with ED) had a higher prevalence of hypogonadism or hyperprolactinemia than did men without ED.
DISCUSSION
In our systematic review, we found a large quantity of "high-grade" evidence indicating that sildenafil, vardenafil, and tadalafil are more effective than placebo in improving erectile function in men with ED over the short term (Յ12 weeks), both in mixed study populations and study populations of men with specific comorbid conditions. The observed between-treatment differences were of clinically meaningful and statistically significant (104, 115, 127) . In trials that directly compared sildenafil, vardenafil, and tadalafil, the magnitude of improvement in erectile function from baseline was similar among the agents. Compared with lower doses, higher doses of sildenafil and vardenafil (but not tadalafil) were associated with modestly greater improvements in erectile function.
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Evidence on whether 1 PDE-5 inhibitor was more or less harmful than another was inconclusive. All PDE-5 inhibitors were associated with increased risk for any or specific adverse events. The reporting of all serious adverse or cardiovascular adverse events was inconsistent and incomplete. The overall rate of serious adverse events in men randomly assigned to PDE-5 inhibitors was about 2.0% or lower and was similar to that in men randomly assigned to placebo. Evidence was insufficient to determine whether treatment with PDE-5 inhibitors increases risk for serious cardiovascular events or NAION in men not receiving nitrates.
Several sources of potential bias may have affected PDE-5 inhibitor trials. First, exclusion of men intolerant of or poorly responsive to previous sildenafil treatment from many tadalafil and vardenafil placebo-controlled trials may have resulted in overestimation of efficacy and underestimation of harms for these agents. Second, the design of head-to-head trials that compared PDE-5 inhibitors may have had biased results in favor of tadalafil through their funding by the manufacturer of tadalafil and their restriction of sildenafil doses. Furthermore, funnel-plot asymmetry and regression analyses suggested possible publication bias for PDE-5 inhibitor trials, although the asymmetry may be explained by methodological or clinical heterogeneity across published studies. Publication bias, if present, may have led to overestimation of the true effect size of clinical benefits associated with use of PDE-5 inhibitors.
Results of trials on the effectiveness and harms of hormonal treatments for ED were inconsistent, probably because of low methodological and reporting quality, differences in patient inclusion criteria, types and doses of testosterone treatment, and outcomes. Results for most trials suggested that testosterone was no more effective than placebo in improving erections or increasing frequency of sexual intercourse.
The evidence on the utility of hormonal blood tests in identifying and affecting therapeutic outcomes for treatable causes of ED is inconclusive. This is in part attributable to the high variability in prevalence of hormonal abnormalities in men with ED across studies and insufficient data on the comparative treatment effectiveness of hormones and PDE-5 inhibitors in men with ED and hormonal abnormalities. Furthermore, consistent evidence was lacking on whether specific clinical features (such as age, comorbid conditions, obesity, hyperlipidemia, and nonresponse to PDE-5 inhibitors) help identify men with hormonal abnormalities among those with ED in primary care settings.
Our review has several limitations. First, many trials had limited methodological and reporting quality, particularly those that directly compared PDE-5 inhibitors and those that evaluated hormonal therapies. Moreover, clinical or methodological heterogeneity and missing information limited the extent of statistical data pooling. Second, the low number and selective reporting of serious cardiovascular events should be interpreted with caution. Third, most RCTs were of short duration (Յ12 weeks), and longer-term efficacy and safety data (Ն6 months) were unavailable.
It is striking that we identified a dearth of credible information on hormonal therapies used in the treatment of ED but an impressive amount of "high-grade" evidence on therapeutic effects of PDE-5 inhibitors compared with placebo for men with ED. This sharp contrast may be explained by the fact that more than 70% of the PDE-5 inhibitor trials in this review were industry funded. This gap in our research base is especially noteworthy in light of the growing popularity of androgen supplementation for various indications in aging men and controversial findings for hormone replacement therapies in women, which are far more extensively studied.
Future efforts are needed to help improve the reporting quality of primary studies. The CONSORT (Consolidated Standards of Reporting Trials) Statement could be considered as a guide for authors reporting trials and journals that publish research related to ED (225) . The conduct of studies using standardized hormonal tests and those designed to identify subgroups of men with ED at increased risk for hormonal disorders would help to further determine the utility of routine hormonal blood tests (226) . Well-designed, long-term PDE-5 inhibitor trials (Ն6 months) are also warranted. In the presence of comorbid conditions or specific causes of ED, the comparison of cause-specific therapies (those targeting underlying causes of ED) to empirical treatments (for example, PDE-5 inhibitors) is important. More direct comparison trials of PDE-5 inhibitor drugs are also needed. 
